Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
K.M. Anderson, P.W.F. Wison, P.M. Odell, W.B. Kannel.
An updated coronary risk profile. A statement for health professionals.
Circulation 1, 83 (1991), pp. 356-362
[2.]
K. Field, M. Thorogood, C. Silagy, C. Normand, C. O'Neill, J. Muir.
Strategies for reducing risk factors in primary care: which is most cost effective?.
BMJ, 310 (1995), pp. 1109-1112
[3.]
T. Van der Weijden, J.A. Knottnerus, A.J.H.A. Ament, H.E.J.H. Stoffers, R.P.T.M. Grol.
Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence.
J Epidemiol Community Health, 52 (1998), pp. 586-594
[4.]
J.R. Downs, M. Clearfield, S. Weis, E. Whitney, D.R. Shapiro, P.A. Beere, et al.
Prevención primaria de los eventos coronarios agudos con lovastatina en varones y mujeres con concentraciones promedio de colesterol. Resultados del AFCAPS/TexCAPS.
Jama, 7 (1998), pp. 305-314
[5.]
J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A. Ross Lorimer, P.W. Macfarlane, et al.
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
N Engl J Med, 333 (1995), pp. 1301-1307
[6.]
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID).
Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels.
N Engl J Med, 339 (1998), pp. 1349-1357
[7.]
Scandinavian Simvastatin Survival Study Group Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease:.
the Scandinavian Simvastatin Survival Study Group (4S).
Lancet, 344 (1994), pp. 1383-1389
[8.]
F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, T.G. Cole, et al.
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
N Engl J Med, 335 (1996), pp. 1001-1009
[9.]
I. Plaza Pérez, F. Villar Álvarez, P. Mata López, F. Pérez Jiménes, A. Maiquez Galán, J.A. Casasnovas Lenguas, et al.
Control de la colesterolemia en España, 2000: un instrumento para la prevención cardiovascular.
Revista Clínica Española, 200 (2000), pp. 494-515
[10.]
E. Ros Rahola.
Las estatinas (I).
7 Días Médicos, 460 (2000), pp. 111-115
[11.]
E.A. Stein, M. Lane, P. Laskarzewski.
Comparison of statins in hypertriglyceridemia.
Am J Cardiol, 81 (1998), pp. 66-69
[12.]
M. Taboada Taboada, M.T. Román León.
Tratamiento farmacológico de las dislipemias. En: Hiperlipidemias. Manual de tratamiento. Ed. Entheos.
Madrid, (2000), pp. 26-43
[13.]
A.J. Jovell, A. García-Altés.
¿Qué estatina es más eficiente? Conceptos y Aplicaciones en evaluación económica.
Atención Primaria, 26 (2000), pp. 333-338
[14.]
R.H. Knopp.
Trtamiento farmacológico de las hiperlipemias.
The New England Journal of Medicine, 341 (1999),
[15.]
E.A. Stein.
Cerivastatina en la hiperlipidemia primaria: análisis multicéntrico de eficacia y seguridad.
Am J Cardiol, 82 (1998), pp. 40-46
[16.]
H. Schuster, J. Berger, F. Luft.
Randomised, double-blind, parallelgroup trial of atorvastatin and fluvastatin on plasma-lipide levels in patients with untreated hyperlipidaemia.
Br J Cardiol, 5 (1998), pp. 1-6
[17.]
R.H. Bradford.
Expanded clinical evaluation of lovastatin (EXCEL) study results: Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia.
Arch Intern Med, 151 (1991), pp. 43-49
[18.]
P. Jones, S. Kafonek, I. Laurora, D. Hunninghake.
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (The Curves Study).
Am J Cardiol, 81 (1998), pp. 582-587
[19.]
P.R. Herbert, J.M. Gaziano, K.S. Chan, C.H. Hennekens.
Reducción del colesterol con estatinas, riesgo de accidentes cerebrovasculares y mortalidad total. Revisión de estudios aleatorios.
JAMA (ed. esp.), 7 (1998), pp. 55-65
[20.]
S. Beil.
Fluvastatin lipid-lowering effect in routine practice conditions (FLIRT). Results of a drug surveillance study.
Clin Drug Invest, 14 (1997), pp. 46-153
[21.]
D. Hunninghake, W. Insull, R. Knopp, M. Davidson, L. Lohrbauer, P. Jones, et al.
Comparison of the efficacy and safety of atorvastatin versus cerivastatin in patients with hypercholesterolemia.
Atherosclerosis, 144 (1999), pp. 1-221
[22.]
A.S. Brown, R.G. Bakker-Arkema, L. Yellen, R.W. Henley, R. Guthrie, C.F. Campbell, et al.
Treating patients with documented atherosclerosis to National cholesterol education program-recommeded lowdensity-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.
JACC, 32 (1998), pp. 665-672
[23.]
P. Jones, J.A. Farmer, M.D. Cressman, J.M. McKenney, J.T. Wright, J.D. Proctor, et al.
Pravastatina una vez al día en pacientes con hipercolesterolemia primaria: estudio dosis-respuesta.
Clin Cardiol, 14 (1991), pp. 146-151
[24.]
W. Krone, N. Schmage, H.W. Breuer.
Comparison of long-term efficacy and safety of cerivastatin versus pravastatin in primary hypercholesterolaemia.
Journal of Clinical Research, 2 (1999), pp. 141-153
[25.]
S.M. Ahmed, M.E. Clasen, J.F. Donnelly.
Tratamiento de la dislipemia en adultos. En: Cardiovascular Medicine (American Family Phisician) Ed.
Medical Trends SL Barcelona, (2000), pp. 1-27
[26.]
H. Lennernäs, G. Fager.
Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors.
Clin Pharmacocinet, 32 (1997), pp. 403-425
[27.]
J. Casajuana, R. Ciurana, F. Lago, A. Maiques, X. Mundet, J. Vilaseca.
Tratamiento farmacológico de la hipercolesterolemia. En: Hipercolesterolemia: Protocolo de Actuación. Ed.
Doyma, Barcelona, (2000), pp. 26-28
[28.]
J.A. Farmer.
Economic implications of lipid-lowering trial: current considerations on selectins a statin.
Am J Cardiol, 82 (1998), pp. 26-31
[29.]
W. Clifford.
The rule of five and the rule of seven in lipid-lowering by statin drugs.
Am J Cardiol, 80 (1997), pp. 106-107
[30.]
X. Badía, P. Russo, E. Attanasio.
Análisis económico comparativo de simvastatina y atorvastatina: resultados del estudio de coste-eficacia con marcadores sustitutivos (Estudio SmaC).
Clinical Therapeutics, 21 (1999), pp. 1788-1796
[31.]
Tárraga PJ, Celada A, Cerdán M, Solera J, Ocaña JM, de Miguel J. Análisis coste-efectividad de atorvastatina frente a simvastatina como tratamiento hipolipemiante en pacientes hipercolesterolémicos en atención primaria.
[32.]
Libro Blanco: Modelo de coste/eficacia en el tratamiento de las hiperlipemias con estatinas..
Gabinete de estudios sociológicos Bernar Krief.
Ed. MILO, Madrid, (1998),
[33.]
S.X. Kong, S.Y. Crawford, S.K. Gandhi, J.D. Seeger, G.T. Schumock, N.P. Lam, et al.
Efficacy of HMG-CoA reductase inhibitors in the treatment of hypercholesterolemia: a metaanalysis of clinical trials.
Clin Ther, 19 (1997), pp. 778-797
[34.]
A.J. Jovell, M.D. Navarro-Rubio, M. Aymerich, M. Serra-Prat.
Metodología de diseño y elaboración de guías de práctica clínica en atención primaria.
Aten Primaria, 20 (1997), pp. 259-266
[35.]
M.E.R. Spearman, K. Summers, V. Moore, R. Jacqmin, G. Smith, S. Groshen.
Cost-effectivenes of initial therapy with 3-hidroxy-3-methilglutaryl coenzyme A reductase inhibitors to treat hypercolesterolaemia in a primary care setting of a managed care organization.
Clin Ther, 19 (1997), pp. 582-602
Copyright © 2004. Elsevier España, S.L. y Sociedad Española de Medicina Rural y Generalista (SEMERGEN)
